Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an
agonist against 4-1BB.
This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD)
and/or the recommended Phase II dose (RP2D) of YH004, both as a single agent (monotherapy)
and in combination with a fixed dose of anti-PD-1 antibody (Toripalimab) in the treatment of
advanced solid tumors and relapsed or refractory non-Hodgkin Lymphoma.